ImmunoGen develops cancer therapeutics through its tumor-activated, prodrug technology, which targets antibodies with cancer-killing drugs.


Updates from The Motley Fool

Latest updates on ImmunoGen from Fool.com.  The Fool has written over 100 articles on ImmunoGen.
ImmunoGen, Inc. Waits for Data

Investors eagerly await data from the biotech's phase 3 trial, but there will be some earlier-sta...

Why ImmunoGen Fell 15% Today

ImmunoGen's shares are falling after its investor conference last week and amid an industry wide ...



Stock Performance

View Interactive IMGN Charts
Sponsored by

Key Data Points

Primary metrics and data points about ImmunoGen.
Current Price: $2.71
Prev Close: $2.61
Open: $2.61
Bid: $2.74
Ask: $2.76
Day's Range: $2.51 - $2.72
52wk Range: $1.51 - $9.78
Volume: 1,458,865
Avg Vol 1,271,855
Market Cap: $237M
P/E (ttm): -1.44
EPS (ttm): ($1.81)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about ImmunoGen.
CAPS Rating 3 out of 5
 
320 Outperform
23 Underperform
CAPS All Stars
 
51 Outperform
5 Underperform

How do you think ImmunoGen will perform against the market?



You pick for ImmunoGen is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Dan Junius, CEO

58% Approve

Based on 16 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for ImmunoGen.

ImmunoGen develops cancer therapeutics through its tumor-activated, prodrug technology, which targets antibodies with cancer-killing drugs.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers